These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24389444)

  • 1. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
    Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
    J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
    Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC
    J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446
    [No Abstract]   [Full Text] [Related]  

  • 4. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
    Ilie MI; Bence C; Hofman V; Long-Mira E; Butori C; Bouhlel L; Lalvée S; Mouroux J; Poudenx M; Otto J; Marquette CH; Hofman P
    Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
    Chiari R; Buttitta F; Iacono D; Bennati C; Metro G; Di Lorito A; Iezzi M; Tiseo M; Mazzoni F; Cappuzzo F; Marchetti A; Crinò L
    Clin Lung Cancer; 2014 Nov; 15(6):470-4. PubMed ID: 25087901
    [No Abstract]   [Full Text] [Related]  

  • 7. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
    Benderra MA; Aspeslagh S; Postel-Vinay S; Bigot L; De Baere T; Loriot Y; Lacroix L; Massard C; Vassal G; André F; Soria JC
    J Thorac Oncol; 2016 Feb; 11(2):e21-3. PubMed ID: 26845121
    [No Abstract]   [Full Text] [Related]  

  • 8. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.
    Salvi S; Varesano S; Boccardo S; Ravetti JL; Canessa PA; Pistillo MP; Ferro P; Fedeli F; Roncella S
    J Thorac Oncol; 2017 Aug; 12(8):e116-e118. PubMed ID: 28748818
    [No Abstract]   [Full Text] [Related]  

  • 10. Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.
    Toyokawa G; Takenoyama M; Watanabe S; Toyozawa R; Inamasu E; Kojo M; Shiraishi Y; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Ichinose Y
    J Thorac Oncol; 2013 Nov; 8(11):e96-8. PubMed ID: 24128725
    [No Abstract]   [Full Text] [Related]  

  • 11. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 12. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
    Shea M; Huberman MS; Costa DB
    J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
    Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
    Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
    [No Abstract]   [Full Text] [Related]  

  • 14. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Awad MM; Katayama R; McTigue M; Liu W; Deng YL; Brooun A; Friboulet L; Huang D; Falk MD; Timofeevski S; Wilner KD; Lockerman EL; Khan TM; Mahmood S; Gainor JF; Digumarthy SR; Stone JR; Mino-Kenudson M; Christensen JG; Iafrate AJ; Engelman JA; Shaw AT
    N Engl J Med; 2013 Jun; 368(25):2395-401. PubMed ID: 23724914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
    J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract]   [Full Text] [Related]  

  • 16. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
    J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract]   [Full Text] [Related]  

  • 17. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Awad MM; Engelman JA; Shaw AT
    N Engl J Med; 2013 Sep; 369(12):1173. PubMed ID: 24047072
    [No Abstract]   [Full Text] [Related]  

  • 19. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma.
    Houang M; Toon CW; Clarkson A; Sioson L; de Silva K; Watson N; Singh NR; Chou A; Gill AJ
    Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):134-8. PubMed ID: 24992173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.